OBJECTIVE: To observe the clinical therapeutic effect of electroacupuncture (EA) combined with tamsulosin hydrochloride sustained release capsule on chronic prostatitis (CP) of damp and heat stasis. METHODS: A total of 70 patients with CP of damp and heat stasis were randomized into an acupuncture plus medication group (35 cases, 4 cases dropped off) and a medication group (35 cases, 5 cases dropped off). In the medication group, tamsulosin hydrochloride sustained release capsule was given orally, 0.2 mg a time, once each night. On the basis of treatment in the medication group, EA was applied at Guanyuan (CV 4), Sanyinjiao (SP 6) and Yinglingquan (SP 9), with disperse-dense wave, 5 mA in intensity for 30 min. Treatment for 30 days was as one course, and totally 3 courses were required in both groups. Before treatment, 1, 2, 3 months into treatment and at the follow-up of 2 months after treatment, the TCM syndrome score and National Institutes of Health chronic prostatitis symptom index (NIH-CPSI) score were observed, and the clinical efficacy was evaluated in both groups. RESULTS: Compared before treatment, the TCM syndrome scores of 3 months into treatment and follow-up were decreased in the acupuncture plus medication group ( CONCLUSION Acupuncture combined with medication can improve the clinical symptoms in patients with CP of damp and heat stasis, and its therapeutic effect is superior to simple western medication.
Acupuncture Points ; Acupuncture Therapy ; Chronic Disease ; Hot Temperature ; Humans ; Male ; Prostatitis/drug therapy* ; Treatment Outcome

Chronic prostatitis is a common disease in male. So far the etiology and pathogenesis of chronic prostatitis, particularly chronic pelvic pain syndrome (CPPS), remain to be elucidated and there is no unified recognition in the treatment of this disease. This article discusses the thoughts and methods for the diagnosis and treatment of chronic prostatitis by combination of TCM and Western medicine systematically.
Chronic Disease ; Combined Modality Therapy ; Drugs, Chinese Herbal ; therapeutic use ; Humans ; Male ; Pelvic Pain ; drug therapy ; Phytotherapy ; Prostatitis ; drug therapy

OBJECTIVETo evaluate the efficacy of Prostat in the treatment of NIH category IIIA prostatitis.

METHODSAn open clinical trial was conducted among 106 NIH category IIIA prostatitis patients. For each patient 1 tablet of Prostat (70 mg P5 + 4 mg EA10) was orally administered twice a day.

RESULTSSubjective symptoms of the patients were significantly improved, particularly those of frequent micturition, urgent urination and peripheral region pains. Objective parameters also showed significant improvement. No adverse reaction associated with the medication was observed.

CONCLUSIONProstat was shown to be an appropriate medicine in the treatment of NIH category IIIA prostatitis, with good curative effect and high safety.

Adult ; Humans ; Male ; Middle Aged ; Phytotherapy ; Pollen ; Prostatitis ; drug therapy ; Treatment Outcome

OBJECTIVETo study the effects of prostadyn sabale capsules on chronic prostatitis (CP).

METHODSOne hundred and twenty-five CP cases were divided into three categories according to National Institutes of Health (NIH) concensus definition and classification of CP:31 of category II. 75 of category IIIA and 19 of category IIIB. All the cases were treated with prostadyn sabale capsules at the dosage of 320 mg twice a day. NIH chronic prostatitis symptom index (NIH-CPSI), routine examination and culture of expressed prostatic secretions (EPS) were prospectively evaluated before and after treatment.

RESULTSThe cure rates of category II, category IIIA and category IIIB were 25.8%, 16.0%, and 21.1% respectively, the general cure rate being 19.2%. The alleviation rate was 63.5% and the total effectivity rate was 82.7%. No side effects were observed.

CONCLUSIONSProstadyn sabale capsules have good effects on CP.

Adult ; Capsules ; Chronic Disease ; Humans ; Male ; Middle Aged ; Phytotherapy ; Prostatitis ; drug therapy ; Serenoa

OBJECTIVETo investigate the curative effect of antiphlogistic agent series on treating chronic nonbacterial prostatitis (CNP).

METHODSOne hundred and sixty patients were randomized into 4 groups for an 8-week clinical observation: group A (oral antiphlogistic medicinal granules only), group B (oral antiphlogistic medicinal granules + retention enema), group C (oral antiphlogistic medicinal granules + rectal), and group D (antiphlogistic medicinal granules + rectally + hip bath). Single blind trials were employed.

RESULTSThe curative rates of the 4 groups were 37.5%, 57.5%, 52.5% and 82.5% respectively, while the total efficacy rates were 42.5%, 82.5%, 77.5% and 92.5% respectively. Compared with groups A, B and C, the curative rate of group D was significantly higher (P < 0.05). The difference in efficacy rates was slight between groups B and D (P < 0.05), but significant between groups A and C (P < 0.05).

CONCLUSIONSCombined treatment therapy can improve the effect of CNP treatment and clear away heat and toxic material. The antiphlogistic agent series, with the effect of motivating blood circulation and removing blood stasis, turned out to be an effective traditional Chinese medicine in treating CNP.

Adult ; Chronic Disease ; Humans ; Male ; Medicine, Chinese Traditional ; Middle Aged ; Prostatitis ; drug therapy

OBJECTIVETo study the therapeutic efficacy of Longqingpian combined with Levofloxacin on Type IIIA prostatitis.

METHODSEighty patients with Type IIIA prostatitis were equally randomized into a Longqingpian group and a Puleanpian group, both treated for 12 weeks. The former were given Longqingpian (once 6 tablets, twice a day) combined with Levofloxacin (once 0.2 g, twice a day) during the first 4 weeks, followed by Longqingpian alone (once 6 tablets, twice a day) for 8 weeks. The latter received Puleanpian (once 4 tablets, 3 times a day) combined with Levofloxacin (once 0.2 g, twice a day) in the initial 4 weeks, followed by Puleanpian alone (once 4 tablets, 3 times a day) for 8 weeks. Before and 4, 8, and 12 weeks after the treatment, all the patients were evaluated by The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) and EPS examination.

RESULTSAfter 4-week, 8-week and 12-week treatment, total score of NIH-CPSI, and the score of pain, voiding symptoms and the quality of life dropped significantly in both groups compared with pre-treatment (P < 0.05 or 0.01), so did the leukocyte count in EPS (P < 0.05). Compared with the 4-week treatment, total score of NIH-CPSI, and the score of pain, voiding symptoms and the quality of life were shown to be significantly different (P < 0.05) in the Longqingpian group from the 8-week and 12-week treatment, except the leukocyte count in EPS. However, there was no significant difference between the 8-week and 12-week treatment in any of the indexes (P > 0.05). Longqingpian effected significant differences in the above indexes (P < 0.05), while Puleanpian did not after the treatment (P > 0.05). And the lecithin Amato body analysis revealed no significant changes in EPS after the treatment in either group (P > 0.05).

CONCLUSIONLongqingpian combined with Levofloxacin is highly effective for Type IIIA prostatitis, by relieving pain and voiding symptoms, decreasing the leukocyte count in EPS and improving the life quality of the patients.

Adult ; Chronic Disease ; Humans ; Levofloxacin ; Male ; Middle Aged ; Ofloxacin ; therapeutic use ; Phytotherapy ; Prostatitis ; drug therapy

OBJECTIVE: To observe the efficacy and safety of Guihuang Formula (GHF) in treating patients with type III prostatitis and Chinese medicine syndrome of dampness-heat and blood stasis. METHODS: Sixty-six patients diagnosed with type III prostatitis with dampness-heat and blood stasis syndrome were randomly divided into the treatment group (GHF) and the control group (tamsulosin) using a random number table, with 33 cases each group. The treatment group received GHF twice a day, and the control group received tamsulosin 0.2 mg once daily before bedtime. Patients in both groups received treatment for 6 weeks and was followed up for 2 weeks. The outcomes included the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score, Chinese Medicine Symptoms Score (CMSS), expressed prostatic secretions (EPS) and adverse events (AEs). RESULTS: After treatment, the NIH-CPSI total score and domain scores of pain discomfort, urination and quality of life decreased significantly from the baseline in both groups (P<0.05). The CMSS score decreased in both groups (P<0.05). The WBC count decreased and lecithin body count increased in both groups (P<0.05). GHF showed a more obvious advantage in reducing the pain discomfort and quality of life domain scores of NIH-CPSI, reducing the CMSS score, increasing the improvement rate of the WBC and lecithin body counts, compared with the control group (P<0.05). There were no significant differences in decreasing urination domain score of NIH-CPSI between two groups (P>0.05). In addition, no serious AEs were observed. CONCLUSION GHF is effective in treating type III prostatitis patients with dampness-heat and blood stasis syndrome without serious AEs. (Registration No. ChiCTR1900026966).
Chronic Disease ; Hot Temperature ; Humans ; Lecithins ; Male ; Pain ; Prostatitis/drug therapy* ; Quality of Life ; Tamsulosin

OBJECTIVETo study the efficacy of biological organic zinc in the treatment of chronic bacterial prostatitis (CBP).

METHODSSixty-one CBP patients were randomized into two groups: Group A (39 cases) was supplemented with organic zinc after routine antibiotic treatment, Group B (22 cases) was given routine antibiotic treatment only. NIH-CPIS (including pain, urinary symptoms, quality of life) and urodynamic indexes were used to evaluate the efficacy of biological organic zinc in the treatment of CBP.

RESULTSThe NIH-CPIS (including pain, urinary symptoms, quality of life) and the maximum urethra closure pressure (MUCP) were markedly decreased after the zinc treatment, compared with the non-zinc group(P < 0.05).

CONCLUSIONIt is suggested that biological organic zinc is effective for the treatment of CBP.

Adult ; Aged ; Bacterial Infections ; drug therapy ; Chronic Disease ; Humans ; Male ; Middle Aged ; Prostatitis ; drug therapy ; physiopathology ; Urodynamics ; Zinc ; therapeutic use

OBJECTIVETo evaluate the clinical efficacy of Qiantongding Decoction in the treatment of type III B prostatitis or chronic pelvic pain syndrome (CPPS).

METHODSSeventy patients with type III B prostatitis / CPPS were randomly divided into an experimental group (n = 36) and a control group (n = 34), the former treated with Qiantongding Decoction, and the latter with oral Indometacin, both for a month. Then their scores on Pelvic Pain Symptom Survey and NIH-CPSI were documented and compared.

RESULTSAn obvious improvement was observed in both groups after the treatment, with significant differences from pre-treatment (P < 0.05), and the experimental group showed a significantly better alleviation of pain than the control (P < 0.05).

CONCLUSIONQiantongding Decoction has an obvious therapeutic effect on type III B prostatitis / CPPS.

Adult ; Drugs, Chinese Herbal ; therapeutic use ; Humans ; Male ; Middle Aged ; Pelvic Pain ; drug therapy ; Phytotherapy ; Prostatitis ; drug therapy ; Treatment Outcome

Fosfomycin (FOM) is an antibiotic with a small relative molecular weight (138.1) and a long half-life, and has a unique chemical structure and antibacterial mechanisms. It exerts a bactericidal activity by inhibiting the early synthesis of bacterial cell walls. It is also a broad-spectrum antibiotic with a good drug tolerance and compliance and a low pressure to bacterial resistance, but no cross-resistance with other antibiotics. Recent studies show the effectiveness of FOM in the treatment of acute uncomplicated urinary tract infections and urogenital tract infections as well, such as prostatitis and epididymitis. This review focuses on the clinical application of FOM in the treatment of infectious diseases of the urogenital tract.
Anti-Bacterial Agents ; therapeutic use ; Epididymitis ; drug therapy ; Fosfomycin ; therapeutic use ; Humans ; Male ; Male Urogenital Diseases ; drug therapy ; Prostatitis ; drug therapy ; Urinary Tract Infections ; drug therapy